Alto Neuroscience, Inc
Los Altos
CA
United States
20 articles about Alto Neuroscience, Inc
-
Alto Neuroscience Announces CEO Amit Etkin, M.D., Ph.D., Named as an Entrepreneur Of The Year® 2023 Bay Area Award Finalist
5/2/2023
Alto Neuroscience Announces CEO Amit Etkin, M.D., Ph.D., Named as an Entrepreneur Of The Year ® 2023 Bay Area Award Finalist.
-
Alto Neuroscience to Present at the Stifel 2023 CNS Days
3/28/2023
Alto Neuroscience today announced that founder and chief executive officer, Amit Etkin, M.D., Ph.D., will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 3:00 p.m. ET.
-
Alto Neuroscience CEO, Amit Etkin M.D., Ph.D., to Participate in National Academies of Sciences, Engineering and Medicine Workshop on Multimodal Biomarkers for Central Nervous System Disorders
3/7/2023
Alto Neuroscience today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in the National Academies of Sciences, Engineering and Medicine Workshop on Multimodal Biomarkers for Central Nervous System (CNS) Disorders: Development, Integration, and Clinical Utility, taking place March 13 - 14, 2023, in Washington, D.C.
-
Alto Neuroscience to Present at the Oppenheimer 33rd Annual Healthcare Conference
3/6/2023
Alto Neuroscience today announced that founder and chief executive officer, Amit Etkin, M.D., Ph.D., will present at the Oppenheimer 33rd Annual Healthcare Conference taking place virtually.
-
Erin R. McQuade, J.D., Joins Alto Neuroscience as General Counsel and Chief Administrative Officer
2/7/2023
Alto Neuroscience today announced the expansion of the company’s leadership team with the addition of Erin R. McQuade, J.D., as general counsel and chief administrative officer (CAO).
-
Alto Neuroscience Announces $60 Million in Additional Financing
1/30/2023
Alto Neuroscience Inc. today announced a $25 million equity investment by new investor, Alpha Wave Ventures.
-
Alto reported positive data from a first-of-its-kind Phase IIb trial of major depressive disorder candidate ALTO-100. -
Alto Neuroscience Announces Positive Results for ALTO-100 in Phase 2 Study Supporting Advancement of First-in-Class Mechanism for Treating Depression
1/10/2023
Alto Neuroscience Inc. today reported results from its Phase 2a study of ALTO-100, demonstrating clear evidence of efficacy and favorable safety in patients with MDD.
-
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America. -
Alto Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/23/2022
Alto Neuroscience Inc. today announced Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023 in San Francisco, CA.
-
Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning to Predict Individual Response to Antidepressants at the 61st Annual Meeting of the American College of Neuropsychopharmacology
12/8/2022
Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning to Predict Individual Response to Antidepressants at the 61st Annual Meeting of the American College of Neuropsychopharmacology.
-
Alto Neuroscience Wins 2022 BioTech Breakthrough and BioSpace’s 2023 Best Places to Work Awards
11/15/2022
Alto Neuroscience today announced it was selected as the 2022 Overall BioPharma Innovation of the Year award winner by BioTech Breakthrough, in addition to being selected as one of BioSpace ’s 2023 Best Places to Work in Biopharma.
-
Alto Neuroscience Announces $35 Million Series B Financing
10/25/2022
Alto Neuroscience today announced the closing of a $35 million Series B financing led by Lightswitch Capital and partners of Alkeon Capital.
-
Alto Neuroscience to Participate in the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit
9/16/2022
Alto Neuroscience to Participate in the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit.
-
BioSpace spoke with three CEOs: Alto Neuroscience’s Dr. Amit Etkin, Omega Therapeutics’ Mahesh Karande and Rain Therapeutics’ Avanish Vellanki about their companies' employment growth. -
During the past several years, data generation, data mining and analytics have progressed to the point that it is now possible to bring precision medicine to psychiatry. -
Alto Neuroscience CEO, Amit Etkin, M.D., Ph.D., Appointed to NIDA’s National Advisory Council on Drug Abuse (NACDA)
5/12/2022
Alto Neuroscience today announced that founder and chief executive officer, Amit Etkin, M.D., Ph.D., has been appointed to serve as a member of the National Institute on Drug Abuse’s (NIDA) National Advisory Council on Drug Abuse (NACDA).
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Total Brain Licenses iSPOT-D for Depression Research to Alto Neuroscience
1/5/2022
Total Brain, a mental health monitoring and support platform, today announced that the company will license its International Study to Predict Optimized Treatment for Depression (iSPOT-D) research data to Alto Neuroscience, a pioneer in precision psychiatric medicine.
-
Cerebral and Alto Neuroscience Enter into Strategic Collaboration to Launch First-Ever Decentralized Study in Precision Psychiatry
12/16/2021
Collaboration born out of joint commitment to bridge the gap between drug discovery and development and commercial scalability in psychiatry.